CD4 T cells provide antibody access to immunoprivileged tissue

Abstract

The present disclosure relates to compositions and methods for treating or preventing a disease or disorder of immunoprivileged tissue. It is described herein that an immunogenic composition which induces production of memory CD4 T cells allows for the access of a therapeutic antibody to the immunoprivileged tissue.

What is claimed is: 
     
         1 . A method for treating or preventing a disease or disorder of an immunoprivileged tissue in a subject in need thereof comprising:
 a.) administering an immunogenic agent to induce a immune response in the subject; and   b.) administering a therapeutic agent, whereby the immune response allows access of the therapeutic agent to the immunoprivileged tissue.   
     
     
         2 . The method of  claim 1 , wherein the immunogenic agent is a vaccine. 
     
     
         3 . The method of  claim 1 , wherein the immunogenic agent comprises an antigen. 
     
     
         4 . The method of  claim 1 , wherein the therapeutic agent is an antibody or antibody fragment that binds to an antigen associated with the disease or disorder. 
     
     
         5 . The method of  claim 4 , wherein the antigen associated with the disease or disorder is different from the antigen of the immunogenic agent. 
     
     
         6 . The method of  claim 1 , wherein the immune response comprises the activation or production of memory CD4 T cells. 
     
     
         7 . The method of  claim 1 , wherein the immunoprivileged tissue is selected from the group consisting of: brain, spinal cord, peripheral nervous system, testes, eye, placenta, and liver. 
     
     
         8 . The method of  claim 1 , wherein the therapeutic agent comprises an antibody or antibody fragment that specifically binds a tumor-specific or tumor-associated antigen. 
     
     
         9 . The method of  claim 8 , wherein the method treats or prevents cancer. 
     
     
         10 . The method of  claim 1 , wherein the therapeutic agent comprises an antibody or antibody fragment that specifically binds an antigen associated with a neurological disorder. 
     
     
         11 . A composition for treating or preventing a disease or disorder of an immunoprivileged tissue in a subject in need thereof comprising:
 a.) an immunogenic agent to induce a immune response in the subject; and   b.) a therapeutic agent.   
     
     
         12 . The composition of  claim 11 , wherein the immunogenic agent is a vaccine. 
     
     
         13 . The composition of  claim 11 , wherein the immunogenic agent comprises an antigen. 
     
     
         14 . The composition of  claim 11 , wherein the therapeutic agent comprises an antibody or antibody fragment that binds to an antigen associated with the disease or disorder. 
     
     
         15 . The composition of  claim 11 , wherein the antigen associated with the disease or disorder is different from the antigen of the immunogenic agent. 
     
     
         16 . The composition of  claim 11 , wherein the immunoprivileged tissue is selected from the group consisting of: brain, spinal cord, peripheral nervous system, testes, eye, placenta, and liver. 
     
     
         17 . The composition of  claim 11 , wherein the therapeutic agent comprises an antibody or antibody fragment that binds to a tumor-specific or tumor-associated antigen.